Processa Pharmaceuticals Inc (PCSA) concluded trading on Thursday at a closing price of $0.30, with 5.37 million shares of worth about $1.61 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -64.75% during that period and on May 29, 2025 the price saw a gain of about 1.00%. Currently the company’s common shares owned by public are about 11.88M shares, out of which, 10.44M shares are available for trading.
Stock saw a price change of 25.76% in past 5 days and over the past one month there was a price change of 32.17%. Year-to-date (YTD), PCSA shares are showing a performance of -65.69% which decreased to -83.16% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.15 but also hit the highest price of $3.10 during that period. The average intraday trading volume for Processa Pharmaceuticals Inc shares is 2.91 million. The stock is currently trading 20.48% above its 20-day simple moving average (SMA20), while that difference is up 6.43% for SMA50 and it goes to -63.81% lower than SMA200.
Processa Pharmaceuticals Inc (NASDAQ: PCSA) currently have 11.88M outstanding shares and institutions hold larger chunk of about 1.44% of that.
The stock has a current market capitalization of $3.61M and its 3Y-monthly beta is at 1.39. It has posted earnings per share of -$3.08 in the same period. It has Quick Ratio of 2.93 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PCSA, volatility over the week remained 6.74% while standing at 6.26% over the month.
Stock’s fiscal year EPS is expected to rise by 77.00% while it is estimated to increase by 1.12% in next year. EPS is likely to grow at an annualized rate of 42.13% for next 5-years, compared to annual growth of 22.65% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on April 25, 2024 offering a Buy rating for the stock and assigned a target price of $8 to it.
